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Abstract 
This issue of Microcirculation focusses on the special topic of “microvessels of the heart” and 
contains five state-of-the-art reviews and one expert article that reflect current efforts to 
address the major gaps in our understanding of these key microvessels. In the adult heart, 
most attention until recently (especially among the clinical cardiology community) has been 
given to the main coronary arteries, which are the culprit vessels in patients with coronary 
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artery disease, including its most serious manifestation, acute myocardial infarction (MI). 
However, due to major advances in efficiently reopening the acutely blocked coronary 
arteries, MI is no longer the killer disease it once was. In contrast, there are few treatment 
options for patients who develop microvascular obstruction during acute MI. Indeed, we have 
a very poor understanding of this disease, or even how heart vessels are initially formed in 
development. This is surprising in light of the essential nature of the cardiac microvessels for 
efficient cardiac function throughout life. The articles in this issue are from six keynote 
speakers at the 66th annual meeting of the British Microcirculation Society at Newcastle 
University and review our understanding of these key vessels from initial development to 
their role in adult heart disease.  
 
Keywords Microvascular obstruction, microRNA, angiogenesis, MSCs, STEMI 
 
This special issue of Microcirculation contains 5 state-of-the-art reviews and one primary 
paper by invited keynote speakers who participated in the 66th annual meeting of the British 
Microcirculation Society (BMS) at Newcastle University on 7th and 8th April 2016.  This was 
the society’s first return “home” since the BMS was founded in Newcastle in 1963.  
Importantly basic scientists and clinicians joined forces in this meeting to consider the role of 
the cardiac microvasculature in maintaining a healthy heart, how these vessels develop and 
how they are regenerated in disease. The overarching goal of the meeting was to drive a 
better understanding of these essential microvessels in order to address the challenging 
problems caused by cardiac microvascular disease in patients. 
 
Major recent advances in our knowledge of how the cardiac vasculature forms during 
development are reviewed in this issue by Nicola Smart [10]. Understanding the 
mechanisms that underpin development of the cardiac vessels is not only important to 
improve our knowledge of how these key vessels form in the embryo, but also because 
many of the cellular and molecular changes that occur during initial vascularisation of the 
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heart are recapitulated in regeneration and repair of the adult heart following injury. 
Increased understanding of these processes will inform improved strategies to promote 
revascularisation of the ischaemic heart or, in cardiac regeneration, to vascularise 
transplanted myocardial cells or tissues.  Insights gained from studying the embryo may also 
reveal novel pathways that can be activated pharmaceutically to promote neo-vessel 
formation in the ischaemic adult heart. There has been a recent surge of studies using 
mouse genetics to track the cellular origins of the coronary vessels, spiced by a measure of 
controversy in the field.  Sometimes the expression patterns of the Cre recombinases used 
for these experiments has led to different interpretations, and the controversies are 
compounded by the fact that two of the key protagonists in the field have the same name 
(Bin Zhou). This review is very timely in bringing together the recent advances in our 
understanding of coronary vessel development in a thorough and cohesive way [10].  
 
Coronary artery disease (CAD) is the single largest cause of mortality worldwide, directly 
causing 12.8% of all deaths [11]. The most serious and acute manifestation of CAD is acute 
myocardial infarction (MI), which is characterized by myocardial damage caused by 
prolonged ischaemia. Therapies to salvage the injured myocardium and reduce cardiac 
damage are essential to improve outcomes for patients. Mesenchymal stem cells (MSCs) 
have been successfully used in pre-clinical studies to revascularise the ischaemic adult heart. 
These cells have immune privilege, as well as the potential to differentiate into different cell 
types. They also release paracrine factors to promote angiogenesis and modulate the 
immune response. These advantages coupled to their ability to activate endogenous cardiac 
cells mean that MSCs have quickly transferred to being used in clinical trials to promote 
heart repair following myocardial infarction (MI). The current take home message is that 
MSCs have great potential to promote heart repair following MI, but clinical trials to date 
suggest they provide at best only modest benefit in improving cardiac function. So the 
challenge now is to build on our understanding of the pro-angiogenic and pro-reparative 
mechanisms of MSCs in order to increase their therapeutic impact. In this issue Qingbo Xu 
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and colleagues [3] summarise current progress in understanding the mechanisms involved 
in MSC-based therapy. One such potential mechanism is that revascularisation is promoted 
by extracellular vesicles released by MSCs, which contain the key proteins and nucleic acids 
to drive neovascularisation. It is even possible that future MSC based therapies may be 
replaced by these cell free mechanisms.  
 
Finally, in our consideration of neovascularisation of the ischaemic heart, Costanza 
Emanueli and colleagues review an explosion of new insights into the roles of miRNAs, 
which are small non-coding RNAs that regulate protein and gene expression [8].  There is 
also growing interest in circulating extracellular vesicles that contain miRNAs within their 
cargo, and how these vesicles are released into the circulation and taken up by recipient 
cells to regulate target gene expression. This recently discovered mechanism of cell-cell 
communication in the heart following injury is currently a focus of many detailed 
investigations [7]. Of particular note is that the extracellular vesicles and their MiRNA 
contents are very stable giving them great potential for future off-the-shelf therapies to 
promote beneficial outcomes such as angiogenesis of the heart in acute ischaemia.  For now, 
we are only just beginning to understand the complex regulatory roles of MiRNAs.  
 
The acutely ischaemic heart is also a critical site where immune cells contribute to heart 
repair. The severity of post-infarction remodelling is dependent not only on the size of the 
infarct, but also on the qualitative characteristics of the reparative response. In their review 
Chen and Frangogiannis [2] elegantly explain how repair of the infarcted myocardium is 
dependent on an integrated immune response. Signals from hypoxic and dying 
cardiomyocytes trigger rapid recruitment of inflammatory immune cells to the ischaemic 
tissue. This is followed by dampening of the pro-inflammatory signals and a transition to 
reparative immune cells, particularly macrophages that promote neovascularisation and 
activation of fibroblasts required for formation of a collagen-based scar. However, the 
process is very complex and MI patients are very heterogeneous so the challenge remains 
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to convert our growing understanding of the immune response in the healing heart to 
successful therapeutic interventions to improve patient outcomes following MI [9]. 
 
Over the last 15 years, clinical therapy for ST elevation myocardial infarction (STEMI) has 
progressed significantly, with the development of primary percutaneous coronary 
intervention (PPCI), whereby the blocked coronary vessel is re-opened to re-perfuse the 
heart. However, there is growing recognition of problems due to occlusion of the cardiac 
microvessels and consequent loss of microvascular perfusion in these patients. 
Microvascular obstruction (MVO) can be observed in up to half of patients undergoing PPCI, 
depending on the cardiac magnetic resonance imaging (MRI) protocol used [13]. Coronary 
MVO results from the interplay between multiple factors, including endothelial dysfunction, 
inflammation, embolization of thrombus and plaque debris, and myocardial oedema [6]. 
MVO is associated with infarct expansion, adverse cardiac remodelling, and worse clinical 
outcomes, irrespective of infarct size (Figure 1)[12,14]. Several clinical trials have 
investigated multiple strategies to minimize coronary MVO, but so far no treatment has 
proven to successfully manage it. The in-depth review by Amedeo Chiribiri and colleagues [4] 
explains the limitations of diagnosing coronary microvascular dysfunction by conventional 
methods such as angiography and then describes invasive as well as non-invasive methods 
for its diagnosis. While the use of a combined pressure/temperature wire under hyperemia in 
the clinic is gaining increasing attention in order to assess the function of the coronary 
microcirculation, either through measuring coronary flow reserve or by using the index of 
microvascular resistance (IMR), non-invasive imaging by either cardiac MRI or Positron 
Emission Tomography (PET) can be used to quantify absolute myocardial blood flow, and 
enable a direct and accurate assessment of coronary microvascular function. The authors 
also provide a very detailed clinical classification of coronary microvascular dysfunction, 
which emphasises the relevance of the coronary microcirculation in non-obstructive CAD, 
cardiomyopathies and reperfusion injury.  
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In his primary research article Paolo Camici and colleagues [5] investigate the effect 
of 8 different antihypertensive drugs on the coronary microcirculation in spontaneous 
hypertensive rats. They found that anti-hypertensive treatment on coronary microvascular 
dysfunction (CMD) is not only dependent on blood pressure reduction, but that compounds 
with comparable anti-hypertensive efficacy may exert different effects on hyperemic 
coronary blood flow and induce different degrees of reverse arteriolar remodelling. All of the 
tested antihypertensive drugs lead to a reduction in medial thickness or interstitial fibrosis. 
However, only perindopril and candesartan significantly improved hyperemic coronary flow. 
The observed lack of correlation between medial thickness and coronary blood flow 
illustrates that endothelial function and arteriolar remodelling can be targeted separately by 
different drugs, and this finding should be considered in patients with dysfunction of the 
coronary microvasculature. As highlighted in this meeting, CMD is gaining recognition as an 
important cause of myocardial ischaemia with critical implications for treatment options and 
patient prognosis [1].   
 
In conclusion, the articles in this issue represent a very timely consideration of recent 
advances in understanding coronary vessel development and therapies for re-
vascularisation of the ischaemic heart. In patients with CAD, we are developing a growing 
appreciation of the critical importance of MVO and how it contributes to cardiac pathology. 
Consideration of how imaging technologies can be used to efficiently visualise MVO in 
patients has opened up opportunities to better understand how MVO impacts on patient 
prognosis and to appropriately prioritise patients for further treatment. Meanwhile an urgent 
goal is to better understand the pathophysiology of MVO so we can meet the clinical 
challenge of improving microvascular reflow in affected heart patients.  
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Figure legends 
Figure 1. Prognostic relevance of Coronary MVO.  Kaplan-Meier survival curve showing 
that patients with coronary MVO have a higher cumulative 2-year event rate than those 
without MVO, (events include cardiovascular death, reinfarction, congestive heart failure, or 
stroke). Figure from: Wu, KC et al [14] 
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